alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with neuropeptide y in 4 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (neuropeptide y) | Trials (neuropeptide y) | Recent Studies (post-2010) (neuropeptide y) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 10,663 | 152 | 2,269 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | neuropeptide y (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0014 | |
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bush, LG; Gibb, JW; Hanson, GR; Midgley, LP | 1 |
| de Montigny, C; Debonnel, G; Fournier, A; Monnet, FP | 1 |
| Gué, M; Junien, JL; Mönnikes, H; Taché, Y; Yoneda, M | 1 |
| Grandt, D; Gué, M; Junien, JL; Reeve, JR; Rivier, J; Taché, Y | 1 |
4 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and neuropeptide y
| Article | Year |
|---|---|
Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen.
Topics: 4-Aminobutyrate Transaminase; Adrenergic beta-Antagonists; Aminocaproates; Aminooxyacetic Acid; Animals; Benzazepines; Carbazoles; Corpus Striatum; Dioxanes; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Administration Schedule; Idazoxan; Male; Naloxone; Neuropeptide Y; Phencyclidine; Prazosin; Psychotropic Drugs; Putamen; Pyrimidines; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Time Factors; Vigabatrin | 1992 |
Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.
Topics: Animals; Cinnamates; Cyclopropanes; Drug Synergism; Guanidines; Haloperidol; Hippocampus; Male; N-Methylaspartate; Neuropeptide Y; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; Receptors, sigma; Spiperone | 1992 |
Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin-releasing factor-induced inhibition of gastric acid secretion in rats.
Topics: Animals; Bombesin; Cinnamates; Cisterna Magna; Corticotropin-Releasing Hormone; Cyclopropanes; Dose-Response Relationship, Drug; Gastric Acid; Humans; Interleukin-1; Male; Microinjections; Neuropeptide Y; Paraventricular Hypothalamic Nucleus; Pentagastrin; Psychotropic Drugs; Pyrimidines; Rats; Rats, Sprague-Dawley | 1992 |
Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.
Topics: Animals; Corticotropin-Releasing Hormone; Gastric Acid; Gastric Mucosa; Male; Neuropeptide Y; Peptide Fragments; Peptide YY; Peptides; Pyrimidines; Rats; Rats, Sprague-Dawley | 1996 |